BioSpace News Archive

ProfoundBio announced that management will be participating in one-on-one meetings at the Morgan Stanley 21st Annual Global Healthcare Conference at the Sheraton New York Times Square Hotel which will take place in New York City on Sept 11-14, 2023.

Israeli medical devices manufacturer BioProtect Ltd. announced today that their BioProtect Balloon Implant™ System has been cleared by the FDA.

i2o Therapeutics, Inc. announced the appointment of Kurt Graves as Chairman, President and CEO.

Delve Bio, a pioneer in metagenomic next-generation sequencing for infectious diseases, announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.

National Resilience, Inc. and Lifera have entered into a non-binding term sheet for the development of biopharma manufacturing capacity in Riyadh, Saudi Arabia.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today praised actions taken by the U.S. Centers for Disease Control and Prevention (CDC) aimed at optimizing hospital sepsis programs in the United States.

Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt Cancer Center, it has commenced treatment of the third patient in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

NorthStar Medical Radioisotopes, LLC (“NorthStar”) is pleased to announce that the first patient has been dosed in a clinical trial using NorthStar’s electron accelerator-produced Cu-67. Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today provided an update on its efforts to expand distribution of its UroShield family of products.